SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-048785
Filing Date
2023-09-19
Accepted
2023-09-19 16:20:10
Documents
16
Period of Report
2023-09-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20230919.htm   iXBRL 8-K 74484
2 EX-1.1 ktra-ex1_1.htm EX-1.1 431384
3 EX-5.1 ktra-ex5_1.htm EX-5.1 23731
4 GRAPHIC img215675602_0.jpg GRAPHIC 6220
5 GRAPHIC img215675602_1.jpg GRAPHIC 6220
  Complete submission text file 0000950170-23-048785.txt   743544

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ktra-20230919.xsd EX-101.SCH 2389
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ktra-20230919_pre.xml EX-101.PRE 11469
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ktra-20230919_lab.xml EX-101.LAB 18331
10 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20230919_htm.xml XML 4691
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 231264059
SIC: 2834 Pharmaceutical Preparations